Enlivex Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Enlivex Therapeutics has a total shareholder equity of $28.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $31.9M and $3.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$25.94m |
| Equity | US$28.56m |
| Total liabilities | US$3.34m |
| Total assets | US$31.90m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1BT's short term assets ($28.6M) exceed its short term liabilities ($2.8M).
Long Term Liabilities: 1BT's short term assets ($28.6M) exceed its long term liabilities ($499.0K).
Debt to Equity History and Analysis
Debt Level: 1BT is debt free.
Reducing Debt: 1BT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1BT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 1BT has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 29.9% each year.